The value of the market for vaccines in the United States will reach $17.4 billion in 2018, according to a study published by Transparency Market Research of Albany, NY. If accurate, the projection would represent a compound annual growth rate (CAGR) of 5.3% during 2012-2018. TMR estimated the US vaccine market at $12.8 billion in 2012.1 2 3
TMR attributes its optimistic forecast to “technological advancements and strong support from governments and other active organizations such as GAVI (Global Alliance for Vaccines and Immunization) and WHO (World Health Organization).” The U.S. market is “witnessing an increasing trend towards development of personalized vaccines and novel vaccines that cures infectious diseases, allergies, and cancers. Additionally, the “[vaccine] industry will undergo continuous improvements in delivery methodologies, vaccine design, and manufacturing in large-scale processes.”3
The report, titled “U.S. Vaccine Market (Human Vaccines: Hepatitis, Influenza, Meningococcal, Pneumococcal, HPV, Combination Vaccines; Animal Vaccines: Canine, Feline, Porcine, Bovine, Ovine, Poultry and Equine)—Industry Analysis, Size, Share, Growth, Trends and Forecast 2014-2020,” breaks down the market into human and animal vaccines.2
The report segments the human vaccines market by type—pediatric and adult—and by antigen—heptatitis A & B, influenza, meningococcal, pneumococcal, human papillomavirus (HPV), combination vaccines (DTaP, DTaP-Hep B-IPV, DTaP-IPV and DTaP-IPV), and others. Primary manufacturers of human vaccines in the U.S. are Sanofi-Pasture, GlaxoSmithKline, Pfizer, Merck, Novartis, and Sanofi-Aventis.1
The report segments the animal vaccines market by animal type—companion animal and livestock. Under the companion animal segment, there are the canine and feline markets. Under livestock, the markets include orcine, bovine, ovine, poultry, and equine.2 The main manufacturers of animal vaccines in the U.S. include Merial (Sanofi-Aventis), Novartis Animal Health, Intervet/Schering-Plough (Merck), and Pfizer Animal Health.1
The human vaccine market is, by far, the larger of the two segments. It accounted for 80% of the market share in 2012 and is expected to continue to dominate the market for the foreseeable future.1
The growth of the human vaccines market is being fueled primarily by pediatric vaccines. TMR notes, “The segment of pediatric vaccines currently has an impressive share of the market and holds good future prospects owing to government compulsion for immunizing children in the U.S.”1
A study earlier this year by Tufts University’s Center for the Study of Drug Development (CSDD) forecast worldwide annual sales of vaccines will hit $40 billion by 2020.4
1 Transparency Market Research. U.S. Vaccines Market to Be Driven by High Demand for Pediatric Vaccines, to Reach US$17.4 Billion by 2018: Transparency Market Research. Business Wire Mar. 19, 2015.
2 Transparency Market Research. U.S. Vaccine Market (Human Vaccines: Hepatitis, Influenza, Meningococcal, Pneumococcal, HPV, Combination Vaccines; Animal Vaccines: Canine, Feline, Porcine, Bovine, Ovine, Poultry and Equine)—Industry Analysis, Size, Share, Growth, Trends and Forecast 2014-2020. TransparencyMarketResearch.com Jan. 27, 2015.
3 Transparency Market Research. U.S. Vaccine Market—Opportunities and Threats. TransparencyMarketResearch.com May 13, 2014.
4 TVR Staff. Tufts University Study Pegs World Vaccine Sales at $40 Billion by 2020. The Vaccine Reaction July 17, 2015.